Myung-Ju Ahn
안명주
MD, PhD
Professor and Chief, Division of Hematology/Oncology血液肿瘤科教授兼主任
👥Biography 个人简介
Prof. Myung-Ju Ahn is a leading Korean oncologist at Samsung Medical Center specializing in lung cancer and head and neck malignancies. She has led pivotal trials in EGFR-targeted therapy, EGFR exon 20 insertions, and novel bispecific antibody approaches, establishing Korea as a key contributor to global oncology evidence.
🧪Research Fields 研究领域
🎓Key Contributions 主要贡献
EGFR Exon 20 Insertions
Led key Asian trials evaluating amivantamab and mobocertinib in EGFR exon 20 insertion-mutated NSCLC, defining treatment standards for this historically drug-resistant subset.
Bispecific Antibody Development
Pioneered clinical development of EGFR-MET bispecific antibody amivantamab in Asian patients, contributing to global regulatory approvals and combination therapy strategies.
Korean NSCLC Research
Built one of Korea's most comprehensive NSCLC biobanks and clinical trial networks, generating molecular epidemiology data informing Korean and global treatment guidelines.
Representative Works 代表性著作
Amivantamab in Patients with NSCLC with EGFR Exon 20 Insertions (CHRYSALIS)
Journal of Clinical Oncology (2021)
Demonstrated 40% ORR of amivantamab in EGFR exon 20-mutated NSCLC after platinum failure, leading to FDA breakthrough therapy designation and approval.
Lazertinib plus Amivantamab vs Osimertinib for EGFR-Mutated NSCLC (MARIPOSA)
New England Journal of Medicine (2024)
Showed superior PFS of lazertinib-amivantamab combination over osimertinib monotherapy, establishing a new combination standard for first-line EGFR-mutated NSCLC.
🏆Awards & Recognition 奖项与荣誉
📄Data Sources 数据来源
Last updated: 2026-01-15 | All information from publicly available academic sources
Related Experts 相关专家
关注 안명주 的研究动态
Follow Myung-Ju Ahn's research updates
留下邮箱，当我们发布与 Myung-Ju Ahn（Samsung Medical Center, Sungkyunkwan University）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment